10-Q · May 7, 2026
Vera Therapeutics reported a significant increase in net loss for Q1 2026, amounting to $121.0 million, or $1.69 per diluted share, lower than analysts' expectations of -$1.35. The company did not generate any revenue…
Earnings analysis · 10-Q
VERA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Vera is transitioning from a clinical-stage biotechnology company to a commercial-stage company following TRUTAKNA's FDA accelerated approval in July 2026, with limited product revenue expected in Q3 2026. Sequential…
Read full summary
Vera is transitioning from a clinical-stage biotechnology company to a commercial-stage company following TRUTAKNA's FDA accelerated approval in July 2026, with limited product revenue expected in Q3 2026. Sequential EPS improved to a $1.52 loss from $1.69, but the year-over-year loss widened and liquidity declined from $714.6 million to $499.2 million. The company says its cash runway extends beyond 12 months, but continued high operating losses, commercialization spending, debt obligations and the need to confirm TRUTAKNA's clinical benefit remain significant risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.52
What stood out
-
Sequential EPS improvement, year-over-year deterioration
Diluted loss improved sequentially to $1.52 per share from $1.69 in Q1 2026, but worsened from $1.20 per share in Q2 2025.
-
TRUTAKNA enters commercial stage
TRUTAKNA received FDA accelerated approval in July 2026 for IgAN, and management expects to record limited product-sale revenue in Q3 2026.
-
Cash reserves remain substantial
Cash, cash equivalents and marketable securities were $499.2 million at June 30, 2026, versus $714.6 million at December 31, 2025, a $215.4 million decline.
-
Runway extends beyond 12 months
Management stated that the $499.2 million liquidity balance is expected to fund planned operations and capital expenditure requirements beyond the next 12 months.
-
No reported control deficiencies
Disclosure controls and procedures were judged effective as of June 30, 2026, and management identified no changes in internal control over financial reporting that materially affected or were reasonably likely to materially affect controls.
-
Organization scales for launch
The company had 361 full-time employees as of June 30, 2026, including 152 engaged in research and development, supporting commercialization and pipeline activities.
What to watch
-
Losses and cash burn remain elevated
Net loss increased to $109.5 million for Q2 2026 from $76.5 million in Q2 2025, while accumulated deficit reached $991.4 million as of June 30, 2026.
-
Debt and covenant constraints
The company had $75.0 million of outstanding borrowings under the 2025 Loan Agreement at June 30, 2026; the loan bears interest at Term SOFR plus 4.95%, subject to a 3.75% Term SOFR floor, and the company does not hedge this exposure.
-
Accelerated-approval confirmation risk
TRUTAKNA's accelerated approval is conditional on confirmatory work: approval was based on UPCR results from ORIGIN 3, while the company must complete the trial and collect eGFR data to demonstrate improvement in kidney function.
-
Commercial launch execution risk
Management expects limited revenue from product sales in Q3 2026 and stated that the company expects to continue incurring net losses until one or more approved products achieve commercial success.
-
First commercial launch
The company stated that it has never successfully commercialized a product and is still building marketing, sales force, market access and distribution capabilities for TRUTAKNA.
-
Milestone and royalty obligations
The company became obligated to pay Ares $20.0 million upon TRUTAKNA's FDA accelerated approval and owes additional Ares milestone payments of up to $131.5 million for other geographic and indication milestones, plus up to $515.0 million tied to worldwide net-sales milestones.
Management's outlook
No explicit numeric revenue or EPS guidance was provided. Management stated it expects limited product revenue during Q3 2026 and that existing cash, cash equivalents and marketable securities of $499.2 million should fund planned operations and capital expenditures beyond the next 12 months.
Earlier filings 4
10-K · February 26, 2026
Vera Therapeutics’ 2025 10-K emphasizes a pivotal inflection: ORIGIN 3 met its primary endpoint (46% reduction from baseline in UPCR; 42% vs placebo, p<0.0001) and the company filed a BLA in November 2025 that received…
10-Q · November 5, 2025
Vera reported a Q3 2025 net loss of $80,293 (three months ended September 30, 2025) and EPS of $(1.26), widening from a net loss of $46,632 and EPS $(0.85) in Q3 2024. The company remains pre-revenue (reported revenue…
10-Q · August 8, 2024
Vera reported a quarterly net loss of $33.708 million (EPS $-0.62) for the three months ended June 30, 2024, wider than the year-ago loss of $20.162 million (EPS $-0.46) and missing the EPS estimate of $-0.56 by $0.06.…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.